Description: Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea. The company also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to treat tropical diseases; Advaxis family to treat HPV-associated cancers and others; PHOTOFRIN for oesophageal and endobronchial cancer, high-grade dysplasia in Barrett's oesophagus, and papillary bladder cancer; ATryn to prevent thromboembolic events; Ember family to treat osteoarthritis, chronic kidney diseases, alport syndrome, and metabolic diseases; and blood factor products. In addition, it develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; dermo-cosmetic line of products, such as Crescita family, Laboratoire Dr. Renaud, Premiology, and Pro-Derm; SEQuaderma, an active dermatology solution; HandMD skin care products; and UrgentRx, a fast-acting, portable over-the-counter medication. Further, the company develops TULSA-PRO, a medical device for prostate ablation; and 3D family diagnostic and prognostic products for cancers and neurological disorders. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company is headquartered in Montreal, Canada.
Home Page: www.gud-knight.com
3400 de Maisonneuve Boulevard West
Montreal,
QC
H3Z 3B8
Canada
Phone:
514 484 4483
Officers
| Name | Title |
|---|---|
| Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A. | Executive Chairman |
| Ms. Samira Sakhia BCom, CA, CPA, MBA | President, CEO & Director |
| Mr. Arvind Utchanah | Chief Financial Officer |
| Ms. Amal Khouri B.Sc., M.B.A. | Chief Business Officer |
| Mr. Stephani Saverio | Vice President of Business Development |
| Mr. Leopoldo Bosano | Vice-President of Manufacturing & Operations |
| Mr. Henrique Dias | Global Director of Marketing |
| Ms. Susan Caroline Emblem | Global Vice President of Human Resources |
| Mr. Jeff Martens | Global Vice President of Commercial |
| Ms. Melanie Groleau | Global Vice President of Medical & Clinical |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 263.1579 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6875 |
| Price-to-Sales TTM: | 1.0785 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 725 |